

Symmetry Medical Inc.  
Form 10-Q  
November 04, 2005  
Table of Contents

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 10-Q**

---

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended October 1, 2005

OR

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number 001-32374

---

**Symmetry Medical Inc.**

(Exact name of registrant as specified in its charter)

Edgar Filing: Symmetry Medical Inc. - Form 10-Q

---

<b>Delaware</b> (State or other jurisdiction of incorporation or organization)	<b>35-1996126</b> (I.R.S. Employer Identification No.)
<b>220 W. Market Street, Warsaw, Indiana</b> (Address of principal executive offices)	<b>46580</b> (Zip code)

**Registrants telephone number, including area code (574) 268-2252**

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant is an accelerated filer (as defined in Exchange Act Rule 12b-2). Yes  No

Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2). Yes  No

The number of shares outstanding of the registrant's common stock as of October 1, 2005, was 34,683,902.

---

**Table of Contents**

**Table of Contents**

	<b>Page</b>
<b>PART I FINANCIAL INFORMATION</b>	
Item 1. Financial Statements:	
<u>Condensed Consolidated Balance Sheets:</u> <u>As of October 1, 2005 and January 1, 2005</u>	1
<u>Condensed Consolidated Statements of Operations:</u> <u>Three and Nine Months Ended October 1, 2005 and October 2, 2004</u>	2
<u>Condensed Consolidated Statements of Cash Flows:</u> <u>Nine Months Ended October 1, 2005 and October 2, 2004</u>	3
<u>Notes to Condensed Consolidated Financial Statements</u>	4
Item 2. <u>Management's Discussion and Analysis of Results of Operations and Financial Condition</u>	10
Item 3. <u>Quantitative and Qualitative Disclosures about Market Risks</u>	14
Item 4. <u>Controls and Procedures</u>	14
<b>PART II OTHER INFORMATION</b>	
Item 1. <u>Legal Proceedings</u>	15
Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	15
Item 6. <u>Exhibits</u>	15
<u>Signatures</u>	16

**Table of Contents****Symmetry Medical Inc.****Condensed Consolidated Balance Sheets***(In Thousands, Except Per Share Data)*

	<b>October 1, 2005</b>	<b>January 1, 2005</b>
	<u>          </u>	<u>          </u>
	<b>(unaudited)</b>	
<b>Assets:</b>		
Current Assets:		
Cash and cash equivalents	\$ 15,475	\$ 4,849
Accounts receivables, net	44,292	39,640
Inventories	35,663	34,083
Refundable income taxes	1,016	2,578
Deferred income taxes	2,106	2,036
Other current assets	3,013	5,635
	<u>          </u>	<u>          </u>
Total current assets	101,565	88,821
Property and equipment, net	91,499	71,854
Interest rate swap valuation asset	658	486
Goodwill	125,260	127,369
Intangible assets, net of accumulated amortization	16,577	17,327
Other assets	899	1,011
	<u>          </u>	<u>          </u>
Total Assets	<u>\$ 336,458</u>	<u>\$ 306,868</u>
<b>Liabilities and Shareholders Equity:</b>		
Current Liabilities:		
Accounts payable	\$ 19,373	\$ 17,908
Accrued wages and benefits	9,925	9,384
Other accrued expenses	2,945	3,012
Income tax payable	2,173	2,008
Revolving line of credit	3,265	1,204
Current portion of capital lease obligations	3,259	3,572
Current portion of long-term debt	1,313	879
	<u>          </u>	<u>          </u>
Total current liabilities	42,253	37,967
Deferred income taxes	9,925	9,547
Capital lease obligations, less current portion	9,141	11,709
Long-term debt, less current portion	27,563	31,500
	<u>          </u>	<u>          </u>
Total Liabilities	<u>88,882</u>	<u>90,723</u>
Commitments and contingencies (Note 10)		
Shareholders Equity:		
Common Stock, \$.0001 par value; 72,410 shares authorized; shares issued (October 1, 2005 34,684; January 1, 2005 33,174)	3	3
Additional paid-in capital	268,487	255,509
Retained earnings (deficit)	(24,671)	(49,178)

Edgar Filing: Symmetry Medical Inc. - Form 10-Q

Accumulated other comprehensive income	3,757	9,811
Total Shareholders' Equity	247,576	216,145
Total Liabilities and Shareholders' Equity	\$ 336,458	\$ 306,868

*See accompanying notes to condensed consolidated financial statements.*

**Table of Contents****Symmetry Medical Inc.****Condensed Consolidated Statements of Operations***(In Thousands, Except Per Share Data)*

	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>October 1, 2005</b>	<b>October 2, 2004</b>	<b>October 1, 2005</b>	<b>October 2, 2004</b>
	<b>(unaudited)</b>	<b>(unaudited)</b>	<b>(unaudited)</b>	<b>(unaudited)</b>
Revenue	\$ 67,228	\$ 54,126	\$ 201,165	\$ 153,053
Cost of Revenue	47,486	38,087	140,593	108,363
Gross Profit	19,742	16,039	60,572	44,690
Selling, general, and administrative expenses	7,455	5,647	21,157	16,975
Operating Income	12,287	10,392	39,415	27,715
Other (income) expense:				
Interest expense	635	3,688	2,347	10,852
Interest rate swap valuation	(65)	(24)	(172)	(809)
Other	927	9	1,811	(230)
Income before income taxes	10,790	6,719	35,429	17,902
Income tax expense	2,567	2,285	10,922	6,108
Net income	8,223	4,434	24,507	11,794
Preferred stock dividends		2,409		7,069
Net income applicable to common shareholders	\$ 8,223	\$ 2,025	\$ 24,507	\$ 4,725
Net income applicable to common shareholders per share:				
Basic	\$ 0.24	\$ 0.13	\$ 0.73	\$ 0.30
Diluted	\$ 0.24	\$ 0.12	\$ 0.71	\$ 0.28
Weighted average common shares and equivalent shares outstanding:				
Basic	34,310	15,789	33,575	15,789
Diluted	34,987	16,612	34,526	16,605

*See accompanying notes to condensed consolidated financial statements.*

**Table of Contents****Symmetry Medical Inc.****Condensed Consolidated Statements of Cash Flows***(In Thousands)*

	Nine Months Ended	
	October 1, 2005	October 2, 2004
	(unaudited)	(unaudited)
<b>Operating activities</b>		
Net Income	\$ 24,507	\$ 11,794
Adjustments to reconcile net income to net cash provided by (used in) operating activities:		
Depreciation	9,504	7,711
Amortization	456	456
(Gain) loss from sale of assets	71	20
Deferred income tax provision	374	(64)
Income tax benefits from exercise of stock options	1,199	
Interest rate swap valuation change	(172)	(809)
Change in operating assets and liabilities:		
Accounts receivable	(6,449)	(6,115)
Other assets	2,212	(2,209)
Inventories	(2,761)	(3,357)
Accounts payable	2,441	5,607
Accrued expenses and other	3,173	3,534
Net cash provided by operating activities	34,555	16,568
<b>Investing activities</b>		
Purchases of property and equipment	(31,354)	(13,619)
Net cash used in investing activities	(31,354)	(13,619)
<b>Financing activities</b>		
Proceeds from bank revolver	37,065	47,580
Payments on bank revolver	(34,695)	(45,311)
Payments on long-term debt and capital lease obligations	(6,452)	(5,591)
Proceeds from the issuance of common stock	11,707	
Payments for redemption of common and preferred stock		(37)
Net cash provided by financing activities	7,625	(3,359)
Effect of exchange rate changes on cash	(200)	42
Net increase (decrease) in cash and cash equivalents	10,626	(368)
Cash and cash equivalents at beginning of period	4,849	2,348
Cash and cash equivalents at end of period	\$ 15,475	\$ 1,980

Edgar Filing: Symmetry Medical Inc. - Form 10-Q

Supplemental disclosures:				
Cash paid for interest	\$	1,837	\$	9,785
Cash paid for income taxes	\$	6,964	\$	2,843
			154,514	494,102
Gross profit		66,399	57,013	185,424
Selling, general and administrative expenses		35,259	31,658	97,498
Legal and settlement expense (recovery), net		361		361
Operating income from continuing operations		30,779	25,355	87,565
Interest and other income, net		961	442	2,371
Income from continuing operations before income taxes		31,740	25,797	89,936
Provision for income taxes		11,780	9,672	33,351
Income from continuing operations		19,960	16,125	56,585
Discontinued operations, net of income taxes:				
Income (loss) from discontinued operations		(65)	1,200	(330)
Loss on disposal		(3)		(662)
Income (loss) from discontinued operations		(68)	1,200	(992)
Net income	\$	19,892	\$	17,325
			\$	55,593
			\$	48,696
Basic earnings per share:				
Income from continuing operations	\$	0.58	\$	0.46
Income (loss) from discontinued operations		(0.01)		0.04
Basic earnings per share	\$	0.57	\$	0.50
			\$	1.64
			\$	1.39
Diluted earnings per share:				
Income from continuing operations	\$	0.56	\$	0.45
Income (loss) from discontinued operations				0.03
Diluted earnings per share	\$	0.56	\$	0.48
			\$	1.59
			\$	1.35
Dividends paid per share	\$	0.075	\$	0.06
Dividends declared per share	\$	0.165	\$	0.06
			\$	0.21
			\$	0.18
Weighted average shares outstanding:				
Basic		34,708	34,847	34,496
Diluted		35,803	36,008	35,612
				34,952
				36,030

See notes to unaudited consolidated financial statements.



Table of Contents

## MAXIMUS, Inc.

## CONSOLIDATED STATEMENTS OF CASH FLOWS

(Dollars in thousands)

(Unaudited)

	Nine Months Ended June 30,	
	2011	2010
<b>Cash flows from operating activities:</b>		
Net income	\$ 55,593	\$ 48,696
Adjustments to reconcile net income to net cash provided by operating activities:		
Loss from discontinued operations	992	20
Depreciation and amortization	16,479	13,648
Deferred income taxes	372	(1,281)
Deferred interest income on note receivable		263
Non-cash equity based compensation	6,936	5,983
Change in assets and liabilities:		
Accounts receivable billed	10,887	10,895
Accounts receivable unbilled	859	(2,539)
Prepaid expenses and other current assets	1,889	(2,004)
Deferred contract costs	(1,849)	1,358
Accounts payable	7,460	8,568
Accrued compensation and benefits	(506)	6,761
Deferred revenue	(13,975)	22,549
Income taxes	(13,217)	9,519
Other assets and liabilities	(1,435)	(2,087)
Cash provided by operating activities continuing operations	70,485	120,349
Cash used in operating activities discontinued operations	(1,086)	(2,152)
Cash provided by operating activities	69,399	118,197
<b>Cash flows from investing activities:</b>		
Acquisition of businesses, net of cash acquired		(10,673)
Purchases of property and equipment	(10,963)	(10,383)
Capitalized software costs	(5,693)	(6,307)
Proceeds from note receivable	65	473
Cash used in investing activities continuing operations	(16,591)	(26,890)
Cash used in investing activities discontinued operations		
Cash used in investing activities	(16,591)	(26,890)
<b>Cash flows from financing activities:</b>		
Employee stock transactions	9,050	2,679
Repurchases of common stock	(16,974)	(22,518)
Tax benefit due to option exercises and restricted stock units vesting	5,227	1,424
Issuance of long-term debt	304	326
Cash dividends paid	(7,241)	(6,295)
Cash used in financing activities continuing operations	(9,634)	(24,384)
Cash used in financing activities discontinued operations		
Cash used in financing activities	(9,634)	(24,384)

## Edgar Filing: Symmetry Medical Inc. - Form 10-Q

Effect of exchange rate changes on cash and cash equivalents	5,521	(1,679)
Net increase in cash and cash equivalents	48,695	65,244
Cash and cash equivalents, beginning of period	155,321	87,815
Cash and cash equivalents, end of period	\$ 204,016	\$ 153,059

*See notes to unaudited consolidated financial statements.*

Table of Contents

**MAXIMUS, Inc.**

**Notes to Unaudited Consolidated Financial Statements**

**For the Three and Nine Months Ended June 30, 2011 and 2010**

*In these Notes to Unaudited Consolidated Financial Statements, the terms the Company, MAXIMUS, us, we, or our refer to MAXIMUS, Inc. its subsidiaries.*

**1. Organization and Basis of Presentation**

*General*

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. The results of operations for the three and nine months ended June 30, 2011 are not necessarily indicative of the results that may be expected for the full fiscal year. The balance sheet at September 30, 2010 has been derived from the audited financial statements at that date but does not include all of the information and notes required by generally accepted accounting principles for complete financial statements.

On May 5, 2011, the Company's Board of Directors declared a two-for-one stock split in the form of a dividend of one share for each outstanding share for shareholders of record on June 15, 2011. The additional shares were distributed on June 30, 2011. This did not change the proportionate interests that stockholders maintained in the Company. On the same date, the Board of Directors declared a cash dividend of nine cents per share. This dividend will be paid on August 31, 2011 to shareholders of record on August 15, 2011. A balance of \$3.1 million has been accrued for this dividend payment. All common stock and per share amounts have been adjusted for the stock split.

These financial statements should be read in conjunction with the consolidated audited financial statements and the notes thereto at September 30, 2010 and 2009 and for each of the three years ended September 30, 2010, included in the Company's Annual Report on Form 10-K for the year ended September 30, 2010 filed with the Securities and Exchange Commission on November 19, 2010.

**2. Recent Accounting Pronouncements**

In September 2009, the FASB issued revised guidance for accounting for contracts that contain more than one contract element. The revised guidance establishes a selling price hierarchy for determining the selling price of each contract element. The guidance also expands the required disclosures. The Company adopted this guidance for all multiple-element arrangements entered into or significantly modified after October 1,

## Edgar Filing: Symmetry Medical Inc. - Form 10-Q

2010. The effect of this new guidance was not significant.

### 3. Property and Equipment

Property and equipment, at cost, consist of the following (in thousands):

	June 30, 2011	September 30, 2010
Land	\$ 1,800	\$ 1,800
Building and improvements	11,485	11,393
Office furniture and equipment	97,245	97,714
Leasehold improvements	4,290	4,833
Property and equipment, gross	114,820	115,740
Less: Accumulated depreciation and amortization	(64,394)	(66,867)
Total property and equipment, net	\$ 50,426	\$ 48,873

Table of Contents**4. Capitalized software**

Software development costs consist of the following (in thousands):

	June 30, 2011	September 30, 2010
Capitalized software development costs	\$ 40,390	\$ 35,648
Less: Accumulated amortization	(12,801)	(10,933)
Total Software development costs, net	\$ 27,589	\$ 24,715

**5. Goodwill and Intangible Assets**

The changes in goodwill for the nine months ended June 30, 2011 are as follows (in thousands):

	Health Services	Human Services	Total
Balance as of September 30, 2010	\$ 43,270	\$ 27,981	\$ 71,251
Foreign currency translation	405	1,596	2,001
Balance as of June 30, 2011	\$ 43,675	\$ 29,577	\$ 73,252

The following table sets forth the components of intangible assets (in thousands):

	As of June 30, 2011			As of September 30, 2010		
	Cost	Accumulated Amortization	Intangible Assets, net	Cost	Accumulated Amortization	Intangible Assets, net
Technology-based intangible assets	\$ 7,362	\$ 4,021	\$ 3,341	\$ 7,160	\$ 3,654	\$ 3,506
Customer contracts and relationships	9,553	7,215	2,338	8,989	5,504	3,485
Non-compete arrangements	256	89	167	243	39	204
Trademark	655	92	563	622	39	583
Total	\$ 17,826	\$ 11,417	\$ 6,409	\$ 17,014	\$ 9,236	\$ 7,778

The intangible assets include \$3.4 million of fully-amortized technology-based assets still in use by the Company. The Company's intangible assets have a weighted average remaining life of 6.4 years, comprising 7.1 years for technology-based intangible assets, 5.2 years for customer contracts and relationships, 2.6 years for non-compete arrangements and 8.6 years for the trademark. Amortization expense for the three months and nine months ended June 30, 2011 was \$0.5 million and \$1.7 million, respectively. Future amortization expense is estimated as follows (in thousands):

Edgar Filing: Symmetry Medical Inc. - Form 10-Q

Three Months ended September 30, 2011	\$	470
Year ended September 30, 2012		1,183
Year ended September 30, 2013		1,104
Year ended September 30, 2014		737
Year ended September 30, 2015		713
Year ended September 30, 2016		713
Thereafter		1,489
Total	\$	6,409

Table of Contents**6. Fair Value Measurements**

The Company is required to disclose the fair value of all assets and liabilities subject to fair value measurement and the nature of the valuation techniques, including their classification within the fair value hierarchy, utilized by the Company in performing these measurements.

The FASB provides a fair value framework which requires the categorization of assets and liabilities into three levels based upon the assumptions (or inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment. The three levels are defined as follows:

- Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
- Level 3: Unobservable inputs that reflect the reporting entity's own assumptions.

The Company's financial assets subject to fair value measurements and the necessary disclosures are as follows (in thousands):

Description	Fair Value as of June 30, 2011	Fair Value Measurements as of June 30, 2011 Using Fair Value Hierarchy		
		Level 1	Level 2	Level 3
Current portion of acquisition-related contingent consideration	\$ (2,969)	\$	\$	\$ (2,969)
Acquisition-related contingent consideration, less current portion	(406)			(406)
Deferred compensation plan liabilities	(11,507)		(11,507)	

The Company's deferred compensation plan liabilities are valued using a market approach, utilizing the value of the underlying investments to identify the fair value. Changes in deferred compensation plan liabilities are recorded in the income statement within Interest and other income, net.

The Company's only acquisition-related contingent consideration liability was incurred with the acquisition of DeltaWare Systems, Inc. (DeltaWare) in February 2010. The fair value of the acquisition-related contingent consideration liability was based on a probability-weighted approach derived from management's own estimates of profitability and sales targets. During the nine month period ended June 30, 2011, management's estimates of DeltaWare's future profitability have been revised, with the result that an additional charge has been recognized. Foreign currency translation adjustments were recorded as a component of other comprehensive income.

The effect on the financial statements is summarized below (in thousands):

Edgar Filing: Symmetry Medical Inc. - Form 10-Q

	Acquisition-related contingent consideration			Total
	Current portion		Long-term portion	
Balance as of September 30, 2010	\$ 923	\$	2,138	\$ 3,061
Additional estimated consideration	50		100	150
Transfer of long-term portion to current portion	1,938		(1,938)	
Foreign currency translation	58		106	164
Balance as of June 30, 2011	\$ 2,969	\$	406	\$ 3,375



Table of Contents

**7. Commitments and Contingencies**

*Litigation*

The Company is involved in various legal proceedings, including contract and employment claims, in the ordinary course of its business. The matters reported on below involve significant pending or potential claims against us.

In March 2009, a state Medicaid agency asserted a claim against MAXIMUS, related to a discontinued business line, in the amount of \$2.3 million in connection with a contract MAXIMUS had through February 1, 2009 to provide Medicaid administrative claiming services to school districts in the state. MAXIMUS entered into separate agreements with the school districts under which MAXIMUS helped the districts prepare and submit claims to the state Medicaid agency which, in turn, submitted claims for reimbursement to the federal government. No legal action has been initiated. The state has asserted that its agreement with MAXIMUS requires the Company to reimburse the state for the amounts owed to the federal government. However, the Company's agreements with the school districts require them to reimburse MAXIMUS for such payments and therefore MAXIMUS believes the school districts are responsible for any amounts disallowed by the state Medicaid agency or the federal government. Accordingly, the Company believes its exposure in this matter is limited to its fees associated with this work and that the school districts will be responsible for the remainder. MAXIMUS has exited the federal healthcare claiming business and no longer provides the services at issue in this matter.

In August 2010, the Company received a draft audit report prepared on behalf of one of its former SchoolMAX customers. The SchoolMAX business line was sold as part of the divestiture of the MAXIMUS Education Systems division in 2008. The draft audit report recommends a refund of approximately \$11.6 million primarily arising out of the alleged failure of MAXIMUS and the buyer of the division to observe the most favored customer pricing term of the contract. MAXIMUS believes the audit report is incorrect and that no amounts are owed as a refund. In February 2011, the client sent a letter to MAXIMUS and the buyer of the business initiating the dispute resolution process under the contract. The client reiterated some of the audit issues previously identified and also raised a number of issues pertaining to services and products delivered under the contract. The client alleges total damages in excess of \$30 million. MAXIMUS and the buyer plan to contest all of the client's claims. The Company also believes that it is entitled to indemnification from the buyer of the business for claims pertaining to services and deliverables.

*Credit Facilities and Performance Bonds*

The Company's Revolving Credit Agreement provides for a senior secured revolving credit facility, with SunTrust Bank as administrative agent, issuing bank and swingline lender, and a syndicate of other lenders (the Credit Facility). The Credit Facility provides for a \$35.0 million revolving line of credit commitment, which may be used (i) for revolving loans, (ii) for swingline loans, subject to a sublimit of \$5.0 million, and (iii) to request the issuance of letters of credit on the Company's behalf, subject to a sublimit of \$25.0 million. The Company may request an increase in the commitment under the Credit Facility, such that the aggregate commitments under the Credit Facility shall at no time exceed \$75.0 million. The credit available under the Credit Facility may be used, among other purposes, to refinance the Company's current indebtedness, to repurchase shares of the Company's capital stock and to finance the ongoing working capital, capital expenditure, and general corporate needs of the Company. The Credit Facility matures on January 25, 2013, at which time all outstanding borrowings must be repaid and all outstanding letters of credit must have been terminated or cash collateralized. At June 30, 2011, letters of credit totaling \$11.0 million were outstanding under the Credit Facility. In addition, a letter of credit for \$1.0 million has been issued on behalf of the Company by another financial institution.

## Edgar Filing: Symmetry Medical Inc. - Form 10-Q

Subject to applicable conditions, the Company may elect interest rates on its revolving borrowings calculated by reference to (i) the prime lending rate as announced by SunTrust Bank (or, if higher, the federal funds effective rate plus 0.50% or the one-month adjusted LIBOR) (a Base Rate Borrowing ), or (ii) the reserve adjusted rate per annum equal to the offered rate for deposits in U.S. dollars for a one (1), two (2), three (3) or six (6) month period in the London Inter-Bank Market (a LIBOR Borrowing ), and, in each case, plus an applicable margin that is determined by reference to the Company's then-current leverage ratio. For swingline borrowings, the Company will pay interest at the rate of interest for a one (1) month LIBOR Borrowing, plus the applicable margin, or at a rate to be separately agreed upon by the Company and the administrative agent.

The Credit Facility provides for the payment of specified fees and expenses, including commitment and letter of credit fees, and contains customary financial and other covenants that require the maintenance of certain ratios including a maximum leverage ratio and a minimum fixed charge coverage ratio. The Company was in compliance with all covenants in the amended Credit Facility as of June 30, 2011. The Company's obligations under the Credit Facility are guaranteed by certain of the Company's direct and indirect subsidiaries (collectively, the Guarantors ) and are secured by substantially all of MAXIMUS' and the Guarantors' present and future tangible and intangible assets, including the capital stock of subsidiaries and other investment property.

Table of Contents

The Company also has a loan agreement with the Atlantic Innovation Fund of Canada. This provides for a loan of up to 1.8 million Canadian Dollars, which must be used for specific technology-based research and development. The loan has no interest charge and is repayable in installments between 2012 and 2022. At June 30, 2011, \$1.8 million (1.8 million Canadian Dollars) was outstanding under this agreement.

Certain contracts require us to provide a surety bond as a guarantee of performance. At June 30, 2011 and September 30, 2010, the Company had performance bond commitments totaling \$18.9 million and \$33.5 million, respectively. These bonds are typically renewed annually and remain in place until the contractual obligations have been satisfied. Although the triggering events vary from contract to contract, in general, we would only be liable for the amount of these guarantees in the event of default in our performance of our obligations under each contract, the probability of which we believe is remote.

*Loss contract*

During the nine month period ended June 30, 2011, the Company recorded a charge of \$7.3 million on a fixed price contract. The Company has recorded a liability of \$4.2 million related to the anticipated loss to be recognized on this contract. The revenue and profitability on this contract are based upon estimated costs to complete the project. The contract is expected to be completed during the 2012 fiscal year.

**8. Legal and Settlement Expense (Recovery), Net**

Legal and settlement expense (recovery), net consists of costs, net of reimbursed insurance claims, related to significant legal settlements and non-routine legal matters, including future probable legal costs estimated to be incurred in connection with those matters. The incremental costs of acquisitions, including legal fees, brokerage fees, and valuation reports, are also included in this balance. Legal expenses incurred in the ordinary course of business are included in selling, general and administrative expense. The following table sets forth the matters that represent legal and settlement expense (recovery), net:

(in thousands)	Three months Ended June 30,		Nine Months Ended June 30,	
	2011	2010	2011	2010
Insurance Recovery				(7,500)
Acquisition expenses related to DeltaWare				254
Other	361		361	1,895
Total	\$ 361	\$	\$ 361	\$ (5,351)

**9. Earnings Per Share**

All common stock share and per share amounts have been adjusted for the two-for-one stock split in June 2011.

## Edgar Filing: Symmetry Medical Inc. - Form 10-Q

The following table sets forth the components of basic and diluted earnings per share (in thousands):

	Three Months Ended June 30,		Nine Months Ended June 30,	
	2011	2010	2011	2010
<b>Numerator:</b>				
Income from continuing operations	\$ 19,960	\$ 16,125	\$ 56,585	\$ 48,716
Income (loss) from discontinued operations	(68)	1,200	(992)	(20)
Net income	\$ 19,892	\$ 17,325	\$ 55,593	\$ 48,696
<b>Denominator:</b>				
Basic weighted average shares outstanding	34,708	34,847	34,496	34,952
<b>Effect of dilutive securities:</b>				
Employee stock options and unvested restricted stock units	1,095	1,161	1,116	1,078
Denominator for diluted earnings per share	35,803	36,008	35,612	36,030

The calculation of dilutive securities did not exclude any of the Company's vesting or exercisable stock options in any of the periods shown.

Table of Contents**10. Stock Repurchase Programs**

All common stock share and per share amounts have been adjusted for the two-for-one stock split in June 2011.

Under resolutions adopted in July 2008 and September 2010, the Board of Directors has authorized the repurchase, at management's discretion, of up to an aggregate of \$175.0 million of the Company's common stock. The resolutions also authorize the use of option exercise proceeds for the repurchase of the Company's common stock. During the nine months ended June 30, 2011 and 2010, the Company repurchased 513,758 and 885,554 common shares at a cost of \$17.9 million and \$22.5 million, respectively. At June 30, 2011, \$115.4 million remained available for future stock repurchases.

As of August 9, 2011, the Company had repurchased an additional 279,500 common shares at a cost of \$11.0 million during the fourth quarter of fiscal 2011.

**11. Comprehensive Income**

Comprehensive income includes net income, plus changes in cumulative foreign currency translation adjustments. The components of comprehensive income for the three and nine months ended June 30, 2011 and 2010 are as follows:

(in thousands)	Three months Ended June 30,		Nine Months Ended June 30,	
	2011	2010	2011	2010
Net income	\$ 19,892	\$ 17,325	\$ 55,593	\$ 48,696
Foreign currency translation adjustments	2,236	(4,334)	8,624	(1,595)
Comprehensive income	\$ 22,128	\$ 12,991	\$ 64,217	\$ 47,101

Table of Contents

**12. Segment Information**

The following table provides certain financial information for each of the Company's business segments (in thousands):

	Three Months Ended June 30,				Nine Months Ended June 30,			
	2011	% (1)	2010	% (1)	2011	% (1)	2010	% (1)
<b>Revenue:</b>								
Health Services	\$ 141,788	100%	\$ 127,307	100%	\$ 409,578	100%	\$ 385,226	100%
Human Services	96,508	100%	84,220	100%	269,948	100%	234,007	100%
Total	238,296	100%	211,527	100%	679,526	100%	619,233	100%
<b>Gross Profit:</b>								
Health Services	35,459	25.0%	32,425	25.5%	108,056	26.4%	94,267	24.5%
Human Services	30,940	32.1%	24,588	29.2%	77,368	28.7%	65,472	28.0%
Total	66,399	27.9%	57,013	27.0%	185,424	27.3%	159,739	25.8%
<b>Selling, general, and administrative expense:</b>								
Health Services	19,536	13.8%	17,916	14.1%	53,958	13.2%	49,527	12.9%
Human Services	16,032	16.6%	13,904	16.5%	43,834	16.2%	38,372	16.4%
Corporate/Other	(309)	NM	(162)	NM	(294)	NM	(25)	NM
Total	35,259	14.8%	31,658	15.0%	97,498	14.3%	87,874	14.2%
<b>Operating income from continuing operations:</b>								
Health Services	15,923	11.2%	14,509	11.4%	54,098	13.2%	44,740	11.6%
Human Services	14,908	15.4%	10,684	12.7%	33,534	12.4%	27,100	11.6%
Consolidating adjustments	309	NM	162	NM	294	NM	25	NM
Subtotal: Segment Operating Income	31,140	13.1%	25,355	12.0%	87,926	12.9%	71,865	11.6%
Legal and settlement recovery (expense), net	(361)	NM		NM	(361)	NM	5,351	NM
Total	\$ 30,779	12.9%	\$ 25,355	12.0%	\$ 87,565	12.9%	\$ 77,216	12.5%

(1) % of respective segment revenue. Changes not considered meaningful are marked NM.

Table of Contents**13. Discontinued Operations**

On September 30, 2010, the Company sold its ERP business for \$5.6 million, net of transaction costs of \$0.7 million, and recognized a pre-tax loss on sale of less than \$0.1 million. The Company had previously recognized a loss on sale of \$1.3 million during the fourth quarter of fiscal 2009. At completion of the sale, the buyer agreed to pay \$1.7 million with the balance payable following completion of certain procedures, including the preparation of a final balance sheet and working capital adjustment. During the quarter ended March 31, 2011, the buyer has informed us that they dispute the valuation of certain assets transferred at the time of sale and are withholding payment of the remaining balance until these matters are resolved. The Company established a reserve of \$1.0 million during the quarter ended March 31, 2011 pending resolution of this matter.

The following table summarizes the operating results of the discontinued operations included in the Consolidated Statements of Operations (in thousands). During the sale negotiations for the ERP business in 2010, a contract previously included within discontinued operations was not transferred and, accordingly, is now included in continuing operations for all periods shown. Accordingly, the results for discontinued operations differ from those disclosed at June 30, 2010.

	<b>Three Months Ended June 30,</b>		<b>Nine Months Ended June 30,</b>	
	<b>2011</b>	<b>2010</b>	<b>2011</b>	<b>2010</b>
<b>Revenue</b>	\$	\$	6,792	\$ 19,717
Income (loss) from discontinued operations	\$	(107)	1,920	(545) (32)
Provision for (benefit from) income taxes		(42)	720	(215) (12)
<b>Income (loss) from discontinued operations</b>	\$	(65)	\$ 1,200	\$ (330) (20)
Loss from discontinued operations		(5)		(1,093)
Benefit from income taxes		(2)		(431)
<b>Loss on disposal</b>		(3)		(662)
<b>Income (loss) from discontinued operations</b>	\$	(68)	\$ 1,200	\$ (992) (20)

Table of Contents

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.**

*The following discussion and analysis of financial condition and results of operations is provided to enhance the understanding of, and should be read in conjunction with, our Consolidated Financial Statements and related Notes included both herein and in our Annual Report on Form 10-K for the year ended September 30, 2010, filed with the Securities and Exchange Commission on November 19, 2010.*

**Forward Looking Statements**

From time to time, we may make forward-looking statements that are not historical facts, including statements about our confidence and strategies and our expectations about revenue, results of operations, profitability, current and future contracts, market opportunities, market demand or acceptance of our products and services. Any statements contained in this Quarterly Report on Form 10-Q that are not statements of historical fact may be forward-looking statements. The words could, estimate, future, intend, may, opportunity, potential, project, anticipates, plans, expect and similar expressions are intended to identify forward-looking statements. These statements may involve risks and uncertainties that could cause our actual results to differ materially from those indicated by such forward-looking statements. These risks are detailed in Exhibit 99.1 to our Annual Report on Form 10-K for the year ended September 30, 2010 and incorporated herein by reference.

**Business Overview**

We provide business process outsourcing services to government health and human services agencies under our mission of *Helping Government Serve the People*.® Our business is focused almost exclusively on administering government-sponsored programs such as Medicaid, the Children's Health Insurance Program (CHIP), health care reform, welfare-to-work, Medicare, child support enforcement and other government programs. Founded in 1975, we are one of the largest pure-play health and human services administrative providers to governments in the United States, Australia, Canada and the United Kingdom. We use our expertise, experience and advanced technological solutions to help government agencies run efficient, cost-effective programs and to improve program accountability, while enhancing the quality of services provided to program beneficiaries.

The Company is managed through two segments, Health Services and Human Services. The Health Services segment provides a variety of business process outsourcing and administrative support services, as well as consulting services for state, provincial and federal programs, such as Medicaid, CHIP, Medicare and the British Columbia Health Insurance Program. The Human Services segment includes a variety of business process outsourcing, case management, job training and support services for programs such as welfare-to-work programs, child support enforcement, K-12 special education and other specialized consulting services.



Table of Contents**Results of Operations***Consolidated*

The following table sets forth, for the periods indicated, selected statements of operations data:

(dollars in thousands, except per share data)	Three Months Ended June 30,		Nine Months Ended June 30,	
	2011	2010	2011	2010
Revenue	\$ 238,296	\$ 211,527	\$ 679,526	\$ 619,233
Gross profit	66,399	57,013	185,424	159,739
Selling, general and administrative expenses	35,259	31,658	97,498	87,874
Selling, general and administrative expenses as a percentage of revenue	14.8%	15.0%	14.3%	14.2%
Operating income from continuing operations excluding legal and settlement expense	31,140	25,355	87,926	71,865
Operating income from continuing operations excluding legal and settlement expense as a percentage of revenue	13.1%	12.0%	12.9%	11.6%
Legal and settlement expense (recovery), net	361		361	(5,351)
Operating income from continuing operations	30,779	25,355	87,565	77,216
Operating margin from continuing operations percentage	12.9%	12.0%	12.9%	12.5%
Interest and other income, net	961	442	2,371	727
Income from continuing operations before income taxes	31,740	25,797	89,936	77,943
Provision for income taxes	11,780	9,672	33,351	29,227
Tax rate	37.1%	37.5%	37.1%	37.5%
Income from continuing operations, net of income taxes	\$ 19,960	\$ 16,125	\$ 56,585	\$ 48,716
Income (loss) from discontinued operations, net of income taxes	(68)	1,200	(992)	(20)
Net income	\$ 19,892	\$ 17,325	\$ 55,593	\$ 48,696
<b>Basic earnings per share:</b>				
Income from continuing operations	\$ 0.58	\$ 0.46	\$ 1.64	\$ 1.39
Income (loss) from discontinued operations	(0.01)	0.04	(0.03)	
Basic earnings per share	\$ 0.57	\$ 0.50	\$ 1.61	\$ 1.39
<b>Diluted earnings per share:</b>				
Income from continuing operations	\$ 0.56	\$ 0.45	\$ 1.59	\$ 1.35
Income (loss) from discontinued operations		0.03	(0.03)	
Diluted earnings per share	\$ 0.56	\$ 0.48	\$ 1.56	\$ 1.35

All per share numbers have been adjusted for the two-for-one stock split in June 2011.

We discuss constant currency revenue information to provide a framework for assessing how our business performed excluding the effect of foreign currency rate fluctuations. To provide this information, revenue from foreign operations is converted into United States Dollars using average exchange rates from the previous fiscal period. Constant currency revenue information is a non-GAAP presentation of our numbers. We believe that constant currency growth provides a useful basis for assessing the Company's performance. The presentation of these non-GAAP numbers is not meant to be considered in isolation, or as an alternative to revenue growth as a measure of performance.

We discuss operating income from continuing operations excluding legal and settlement expense. Legal and settlement expense, which is defined below, is broken out on the face of our financial statements as we believe that the exclusion of these costs and insurance recoveries from operating income provides a useful basis for assessing the Company's performance. Operating income from continuing operations excluding legal and settlement expense is a non-GAAP presentation of our numbers. The presentation of these non-GAAP numbers is not meant to be considered in isolation, or as an alternative to operating income as a measure of performance.

## Edgar Filing: Symmetry Medical Inc. - Form 10-Q

### Table of Contents

Revenue increased 12.7%, or 7.9% on a constant currency basis, for the three months ended June 30, 2011, compared to the same period in fiscal 2010. Revenue increased 9.7%, or 6.7% on a constant currency basis, for the nine months ended June 30, 2011, compared to the same period in fiscal 2010. This growth was driven by organic growth in both our Human Services and Health Services segments and across all geographies. The results of the Company's segments are considered in more detail below.

Selling, general and administrative expense (SG&A) consists of costs related to general management, marketing and administration. These costs include salaries, benefits, bid and proposal efforts, travel, recruiting, continuing education, employee training, non-chargeable labor costs, facilities costs, printing, reproduction, communications, equipment depreciation, intangible amortization and legal expenses incurred in the ordinary course of business. During the current period, SG&A as a percentage of revenue has been consistent with that recorded in the comparative periods of fiscal 2010. The Company routinely experiences fluctuations between its SG&A and its gross profit margin and believes operating margin is a more appropriate metric for measuring performance.

Legal and settlement expense (recovery), net consists of costs, net of reimbursed insurance claims, related to significant legal settlements and non-routine legal matters, including future probable legal costs estimated to be incurred in connection with those matters. The incremental costs of acquisitions, including legal fees, brokerage fees and valuation reports, are also included in this balance. Legal expenses incurred in the ordinary course of business are included in selling, general and administrative expense. The Company recorded a legal and settlement expense of \$0.4 million for the three and nine month period ended June 30, 2011. During the nine month period ended June 30, 2010, the Company experienced miscellaneous legal settlement expenses and incurred costs related to the acquisition of DeltaWare, offset by a \$7.5 million insurance recovery related to a legal settlement in fiscal 2008.

Operating income from continuing operations for the three months ended June 30, 2011 increased 21.4% to \$30.8 million compared with the same period in the prior year and increased 22.8% excluding the effect of legal and settlement expense. Operating income from continuing operations for the nine months ended June 30, 2011 increased 13.4% to \$87.6 million compared with the same period in the prior year and increased 22.3% excluding the effect of legal and settlement expense. Our expenses in both cost of revenue and SG&A are affected by seasonal fluctuations in employee benefits and payroll taxes. In the current period, the Company made a change in their vacation policy that resulted in an additional charge. This charge was largely offset by decreases in the costs of other taxes and benefits in the current period. Other increases in operating income in both the Health and Human Services Segments are discussed in greater detail below.

Interest and other income, net includes interest earned on cash and cash equivalents and on a note received by the Company for the disposal of a business in fiscal 2008, offset by charges related to the deferred compensation plan and acquisition-related contingent consideration related to DeltaWare. The balance also includes foreign exchange gains and losses, which are typically immaterial. Interest and other income, net has increased from \$0.4 million to \$1.0 million for the three months ended June 30, 2011, compared with the same period in the prior year, and from \$0.7 million to \$2.4 million for the nine months ended June 30, 2011, compared to the same period in the prior year. The increase is caused by increased cash balances and higher yields on investments.

The Company's tax rate for the three month and nine month periods ended June 30, 2011 was 37.1%, compared with 37.5% in the same periods in fiscal 2010. The decline is caused by the increase in overseas-sourced income in the current year, which typically incurs lower rates than those charged in the United States.

Income from continuing operations, net of income taxes, was \$20.0 million, or \$0.56 per diluted share, for the three months ended June 30, 2011, compared with \$16.1 million, or \$0.45 per diluted share, for the same period in fiscal year 2010. For the nine month periods ended June 31, 2011 and 2010, income from continuing operations, net of income taxes was \$56.6 million and \$48.7 million, or \$1.59 and \$1.35 per

## Edgar Filing: Symmetry Medical Inc. - Form 10-Q

diluted share, respectively. Improvements in operating income were driven by improvements in segment results, which are discussed in greater detail below, as well as the beneficial effect of foreign exchange and a declining tax rate. These benefits were offset by an insurance recovery of \$7.5 million in fiscal 2010, which did not reoccur in fiscal 2011.

## Edgar Filing: Symmetry Medical Inc. - Form 10-Q

### Table of Contents

#### *Health Services Segment*

(dollars in thousands)	Three Months Ended June 30,		Nine Months Ended June 30,	
	2011	2010	2011	2010
Revenue	\$ 141,788	\$ 127,307	\$ 409,578	\$ 385,226
Gross profit	35,459	32,425	108,056	94,267
Operating income	15,923	14,509	54,098	44,740
Operating margin percentage	11.2%	11.4%	13.2%	11.6%

Revenue increased by 11.4%, or 10.7% on a constant currency basis, for the three months ended June 30, 2011, compared to the same period in fiscal year 2010. Revenue increased by 6.3%, or 5.8% on a constant currency basis, for the nine months ended June 30, 2011, compared to the same period in fiscal year 2010. Revenue increases have been driven by new work and expansion on existing contracts.

Operating profit margin for the three month period ended June 30, 2011 was 11.2%, compared with 11.4% in the same period last year. During the quarter, start-up costs were incurred for a project which commenced in mid-June. Operating profit margin for the nine month period ended June 30, 2011 was 13.2%, compared with 11.6% in the same period in the prior year. This growth was driven by a spike in accretive, transaction-based work within our health appeals business as well as favorable timing on certain contracts.

#### *Human Services Segment*

(dollars in thousands)	Three Months Ended June 30,		Nine Months Ended June 30,	
	2011	2010	2011	2010
Revenue	\$ 96,508	\$ 84,220	\$ 269,948	\$ 234,007
Gross profit	30,940	24,588	77,368	65,472
Operating income	14,908	10,684	33,534	27,100
Operating margin percentage	15.4%	12.7%	12.4%	11.6%

Revenue increased by 14.6%, or 3.7% on a constant currency basis, for the three months ended June 30, 2011, compared to the same period in fiscal year 2010. Revenue increased by 15.4%, or 8.1% on a constant currency basis, for the nine months ended June 30, 2011, compared to the same period in fiscal year 2010. Revenue growth was driven by our international welfare-to-work businesses, particularly in Australia. In the United Kingdom, we experienced acceleration of certain revenues related to the termination of the Flexible New Deal contract, partially offset by costs relating to the start-up of the replacement Work Programme contract, which commenced in June.

Margins for the three month and nine month periods ended June 30, 2011 improved compared with the same periods in fiscal 2010. Margin improvement was driven by improved contract performance in Australia and the acceleration of Flexible New Deal revenues. Operating income and margins for fiscal 2011 were dampened by cost growth on a single fixed-price contract. Charges of \$7.3 million were recorded against this

## Edgar Filing: Symmetry Medical Inc. - Form 10-Q

contract during the nine months ended June 30, 2011. No charges relating to cost growth were recorded in the current quarter. Revenue and profitability on this contract are based upon estimated costs to complete the project. The contract is anticipated to be completed during the 2012 fiscal year.

### *Discontinued operations*

On September 30, 2010, the Company sold its ERP business for \$5.6 million, net of transaction costs of \$0.7 million, and recognized a pre-tax loss on sale of less than \$0.1 million. The Company had previously recognized a loss on sale of \$1.3 million during the fourth quarter of fiscal 2009. At completion of the sale, the buyer agreed to pay \$1.7 million with the balance payable following completion of certain procedures, including the preparation of a final balance sheet and working capital adjustment. During the quarter ended March 31, 2011, the buyer has informed us that they dispute the valuation of certain assets transferred at the time of sale and are withholding payment of the remaining balance until these matters are resolved. The Company established a reserve of \$1.0 million during the quarter ended March 31, 2011 pending resolution of this matter. The losses recorded in the current quarter and year-to-date period reflect adjustments made to the value of the assets disposed of and adjustments to the loss on sale caused by the reserve.

Table of Contents**Liquidity and Capital Resources***Current Economic Environment*

Within the United States, the current economic environment facing state and local governments continues to be challenging. Over the past few years, states have faced declining tax revenues, with increasing demand for critical services from the most vulnerable members of society. At the same time, states are generally required to balance their budgets each year. Certain states may delay payments to vendors as a result of budgetary constraints. In prior periods, the Company has faced short-term payment delays from state customers, all of which were ultimately recovered. The Company believes its liquidity and capital positions are adequate to weather short-term payment delays. In the event of more protracted delays, the Company may be required to seek additional capital sources, amend payment terms or take other actions. Extended payment delays could adversely affect the Company's cash flows, operations and profitability.

The Company believes that demand for its services in its core areas of health and human services will remain strong, driven by the need for governments to fulfill federal mandates and do more with less.

The situation for international governments is also challenging, with each of the areas in which MAXIMUS operates experiencing unique local issues in addition to general global economic factors.

*Cash Flows*

<b>(dollars in thousands)</b>	<b>Nine Months Ended June 30,</b>	
	<b>2011</b>	<b>2010</b>
<b>Net cash provided by (used in):</b>		
Operating activities – continuing operations	\$ 70,485	\$ 120,349
Operating activities – discontinued operations	(1,086)	(2,152)
Investing activities – continuing operations	(16,591)	(26,890)
Financing activities – continuing operations	(9,634)	(24,384)
Effect of exchange rate changes on cash and cash equivalents	5,521	(1,679)
Net increase in cash and cash equivalents	\$ 48,695	\$ 65,244

Cash provided by operating activities from continuing operations for the nine months ended June 30, 2011 was \$70.5 million, compared with \$120.3 million in the same period in fiscal year 2010. This decline has occurred notwithstanding a \$6.9 million increase in net income and a \$2.8 million increase in amortization and depreciation. The principal driver of the decline is the difference in cash flows related to the United Kingdom business, resulting in approximately \$20.0 million less in the current fiscal period than that of the comparative period in fiscal 2010. In fiscal 2010, the Company commenced a contract which provided significant cash inflows resulting in deferred revenue. The contract will terminate at the end of the current fiscal year and, accordingly, deferred revenue has been reduced.





## Edgar Filing: Symmetry Medical Inc. - Form 10-Q

### Table of Contents

Cash used in operating activities from discontinued operations for the nine months ended June 30, 2011 was \$1.1 million, compared with \$2.2 million in the same period in fiscal year 2010. During the nine month period ended June 30, 2011, the principal cash outflow related to the settlement of accounts payable and payroll liabilities which had not been transferred to the acquirer on the sale of the business, as well as certain additional liabilities identified after the acquisition. In the comparative period in fiscal year 2010, the business was recording losses, including a charge related to the termination of a contract, resulting in cash outflows.

Cash used in investing activities from continuing operations for the nine months ended June 30, 2011 was \$16.6 million, compared to \$26.9 million for the same period in fiscal year 2010. The principal driver of the change was the acquisition of DeltaWare in February 2010.

Cash used in financing activities from continuing operations for the nine months ended June 30, 2011 was \$9.6 million, compared to \$24.4 million for the same period in fiscal year 2010. This change is driven by: (1) an increase of \$6.4 million of funds received from employee stock transactions, particularly proceeds from stock option exercises; (2) an increase of \$3.8 million of tax benefits from the Company's restricted stock units, reflecting the increased share price over that of RSU issuance; and (3) a decline of \$5.5 million in repurchases of common stock. These benefits were offset by a \$0.9 million increase in our dividend payment, reflecting the increase in payments from 18 cents to 21 cents per share.

Foreign exchange rate fluctuations increased the cash balance by \$5.5 million in the nine month period ended June 30, 2011. The principal driver of this change was the strengthening of the Australian Dollar against the United States Dollar.

To supplement our statements of cash flows presented on a GAAP basis, we use the non-GAAP measure of free cash flows from continuing operations to analyze the funds generated from operations. We believe free cash flow from continuing operations is a useful basis for comparing our performance with our competitors. The presentation of non-GAAP free cash flows from continuing operations is not meant to be considered in isolation, or as an alternative to net income as an indicator of performance, or as an alternative to cash flows from operating activities as a measure of liquidity. We calculate free cash flow from continuing operations as follows:

(dollars in thousands)	Nine Months Ended June 30,	
	2011	2010
Cash provided by operating activities – continuing operations	\$ 70,485	\$ 120,349
Purchases of property and equipment	(10,963)	(10,383)
Capitalized software costs	(5,693)	(6,307)
Free cash flow from continuing operations	\$ 53,829	\$ 103,659

#### *Repurchases of the Company's common stock*

Under resolutions adopted in July 2008 and September 2010, the Board of Directors has authorized the repurchase, at management's discretion, of up to an aggregate of \$175.0 million of the Company's common stock. The resolutions also authorize the use of option exercise proceeds for the repurchase of the Company's common stock. During the nine months ended June 30, 2011 and 2010, the Company repurchased 513,758 and 885,554 common shares at a cost of \$17.9 million and \$22.5 million, respectively. At June 30, 2011, \$115.4 million remained available for future stock repurchases. As of August 9, 2011, the Company had repurchased an additional 279,500 common shares at a cost of \$11.0 million.

during the fourth quarter of fiscal 2011.

*Credit arrangements*

The Company's Revolving Credit Agreement provides for a senior secured revolving credit facility, with SunTrust Bank as administrative agent, issuing bank and swingline lender, and a syndicate of other lenders (the Credit Facility). The Credit Facility matures on January 25, 2013, at which time all outstanding borrowings must be repaid and all outstanding letters of credit must have been terminated or cash collateralized. At June 30, 2011, there were no outstanding borrowings under the Credit Facility and letters of credit totaling \$12.0 million were outstanding, including a \$1.0 million letter with another financial institution. The Company was in compliance with all covenants required by the Credit Facility.

The Company also has a loan agreement with the Atlantic Innovation Fund of Canada. This provides for a loan of up to 1.8 million Canadian Dollars, which must be used for specific technology-based research and development. The loan has no interest charge and is repayable in installments between 2012 and 2022. At June 30, 2011, \$1.8 million (1.8 million Canadian Dollars) was outstanding under this agreement.

Table of Contents

Certain contracts require us to provide a surety bond as a guarantee of performance. At June 30, 2011 and September 30, 2010, the Company had performance bond commitments totaling \$18.9 million and \$33.5 million, respectively. These bonds are typically renewed annually and remain in place until the contractual obligations have been satisfied. Although the triggering events vary from contract to contract, in general, we would only be liable for the amount of these guarantees in the event of default in our performance of our obligations under each contract, the probability of which we believe is remote.

*Other*

Our working capital at June 30, 2011 and September 30, 2010, calculated as the difference between current assets and current liabilities, was \$245.6 million and \$191.5 million, respectively. At June 30, 2011, we had cash and cash equivalents of \$204.0 million and debt of \$1.8 million. Management believes this liquidity and financial position, along with the revolving credit facility discussed above, provides sufficient liquidity to continue any contemplated stock repurchase program (depending on the price of the Company's common stock), to pursue selective acquisitions, and to consider the continuation of dividends on a quarterly basis. Restricted cash represents amounts held as collateral balances for property leases and credit cards in overseas locations.

Under the provisions of certain contracts, we may receive funds on an accelerated basis that are treated as deferred revenue. The Company's current contract within the United Kingdom, under the Flexible New Deal was established in this manner with significant cash funds in excess of revenues during fiscal 2010 and revenues in excess of cash receipts in fiscal 2011. This contract was terminated in the current quarter and the replacement contracts will not provide the same level of up-front cash benefit and will provide most payments on a contingent basis, which may take up to two years to be realized. This is expected to have an adverse effect of between \$4 million and \$6 million in cash flows in fiscal 2012, which management estimates will be recouped in fiscal 2013. The Company believes it has sufficient liquidity to manage these cash flows.

Under the provisions of certain long-term contracts, we may incur certain reimbursable transition period costs. During the transition period, these expenditures result in the use of our cash and in our entering into lease financing arrangements for a portion of the costs. Reimbursement of these costs may occur in the set-up phase or over the contract operating period. Related revenue may also be deferred during the set-up phase. As of June 30, 2011, \$8.6 million in net costs had been incurred and reported as deferred contract costs on our consolidated balance sheet.

On May 5, 2011, the Company's Board of Directors declared a cash dividend of \$0.09 for each share of the Company's common stock outstanding. This dividend is payable on August 31, 2011 to shareholders of record on August 15, 2011. This is anticipated to represent a payment of \$3.1 million.

We believe that we will have sufficient resources to meet our currently anticipated capital expenditure and working capital requirements for at least the next twelve months.

**Critical Accounting Policies and Estimates**

## Edgar Filing: Symmetry Medical Inc. - Form 10-Q

Our discussion and analysis of financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities and the reported amounts of revenue and expenses. On an ongoing basis, we evaluate our estimates including those related to revenue recognition and cost estimation on certain contracts, the realizability of goodwill, and amounts related to income taxes, certain accrued liabilities and contingencies and litigation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates.

We believe that we do not have material off-balance-sheet risk or exposure to liabilities that are not recorded or disclosed in our financial statements. While we have significant operating lease commitments for office space, these commitments are generally tied to the period of performance under related contracts. Additionally, although on certain contracts we are bound by performance bond commitments and standby letters of credit, we have not had any defaults resulting in draws on performance bonds. Also, we do not speculate in derivative transactions.

During the nine months ended June 30, 2011, there were no significant changes to the critical accounting policies we disclosed in Management's Discussion and Analysis of Financial Condition and Results of Operations in the Company's Annual Report on Form 10-K for the year ended September 30, 2010.

Table of Contents

**Recent Accounting Pronouncements**

In September 2009, the FASB issued revised guidance for accounting for contracts that contain more than one contract element. The revised guidance establishes a selling price hierarchy for determining the selling price of each contract element. The guidance also expands the required disclosures. The Company adopted this guidance for all multiple-element arrangements entered into or significantly modified after October 1, 2010. The effect of this new guidance was not significant.

**Item 3. Quantitative and Qualitative Disclosures about Market Risk.**

We believe that our exposure to market risk related to the effect of changes in interest rates, foreign currency exchange rates, commodity prices and other market risks with regard to instruments entered into for trading or for other purposes is immaterial.

The Company is exposed to foreign exchange fluctuations in the Australian Dollar, Canadian Dollar, and British Pound. During the nine month period ended June 30, 2011, the Company earned approximately 32% of revenues from foreign subsidiaries. The Company mitigates its foreign exchange risks through maintaining sufficient capital within its foreign subsidiaries to support the short-term and long-term requirements of the businesses. The Company's foreign subsidiaries typically incur costs in the same currency as they earn revenues, thus limiting the Company's exposure to unexpected fluctuations in currency. The operations of the businesses in the United States do not depend upon cash flows from foreign subsidiaries.

In the nine month period ended June 30, 2011, an additional 1% fluctuation in the currencies listed above would have resulted in a difference of \$2.2 million of revenue and \$0.4 million of operating profit.

**Item 4. Controls and Procedures.**

(a) Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, our principal executive officer and principal financial officer concluded that these disclosure controls and procedures were effective and designed to ensure that the information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the requisite time periods.

(b) Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) identified in connection with the evaluation of our internal control that occurred during our last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## PART II. OTHER INFORMATION

### ITEM 1. *Legal Proceedings.*

The Company is involved in various legal proceedings, including contract and employment claims, in the ordinary course of its business. The matters reported on below involve significant pending or potential claims against us.

In March 2009, a state Medicaid agency asserted a claim against MAXIMUS, related to a discontinued business line, in the amount of \$2.3 million in connection with a contract MAXIMUS had through February 1, 2009 to provide Medicaid administrative claiming services to school districts in the state. MAXIMUS entered into separate agreements with the school districts under which MAXIMUS helped the districts prepare and submit claims to the state Medicaid agency which, in turn, submitted claims for reimbursement to the federal government. No legal action has been initiated. The state has asserted that its agreement with MAXIMUS requires the Company to reimburse the state for the amounts owed to the federal government. However, the Company's agreements with the school districts require them to reimburse MAXIMUS for such payments and therefore MAXIMUS believes the school districts are responsible for any amounts disallowed by the state Medicaid agency or the federal government. Accordingly, the Company believes its exposure in this matter is limited to its fees associated with this work and that the school districts will be responsible for the remainder. MAXIMUS has exited the federal healthcare claiming business and no longer provides the services at issue in this matter.

In August 2010, the Company received a draft audit report prepared on behalf of one of its former SchoolMAX customers. The SchoolMAX business line was sold as part of the divestiture of the MAXIMUS Education Systems division in 2008. The draft audit report recommends a refund of approximately \$11.6 million primarily arising out of the alleged failure of MAXIMUS and the buyer of the division to observe the most favored customer pricing term of the contract. MAXIMUS believes the audit report is incorrect and that no amounts are owed as a refund. In February 2011, the client sent a letter to MAXIMUS and the buyer of the business initiating the dispute resolution process under the contract. The client reiterated some of the audit issues previously identified and also raised a number of issues pertaining to services and products delivered under the contract. The client alleges total damages in excess of \$30 million. MAXIMUS and the buyer plan to contest all of the client's claims. The Company also believes that it is entitled to indemnification from the buyer of the business for claims pertaining to services and deliverables.

Table of Contents

**Item 1A. Risk Factors.**

In connection with information set forth in this Form 10-Q, the factors discussed under Risk Factors in our Form 10-K for fiscal year ended September 30, 2010 should be considered. The risks included in the Form 10-K could materially and adversely affect our business, financial condition and results of operations. There have been no material changes to the factors discussed in our Form 10-K.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.**

(c) The following table sets forth the information required regarding repurchases of common stock that we made during the three months ended June 30, 2011:

Period		Total Number of Shares Purchased (1)	Average Price Paid per Share(1)	Total Number of Shares Purchased as Part of Publicly Announced Plans (1)(2)	Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plan (in thousands)
Apr. 1, 2011	Apr. 30, 2011		\$		\$ 123,233
May 1, 2011	May 31, 2011				\$ 124,565
Jun. 1, 2011	Jun. 30, 2011	238,600	39.49	238,600	\$ 115,439
Total		238,600	\$ 39.49	238,600	

(1) All share numbers and prices have been adjusted to reflect the two-for-one stock split which occurred in June 2011.

(2) Under resolutions adopted in July 2008 and September 2010, the Board of Directors has authorized the repurchase, at management's discretion, of up to an aggregate of \$175.0 million of the Company's common stock. The resolution also authorized the use of option exercise proceeds for the repurchase of the Company's common stock.

**Item 6. Exhibits.**

The Exhibits filed as part of this Quarterly Report on Form 10-Q are listed on the Exhibit Index immediately following the Signatures. The Exhibit Index is incorporated herein by reference.





Table of Contents

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

MAXIMUS, INC.

Date: August 9, 2011

By:

/s/ David N. Walker  
David N. Walker  
Chief Financial Officer  
(On behalf of the registrant and as Principal Financial  
and Accounting Officer)

Table of Contents

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
31.1	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Section 906 Principal Executive Officer Certification.
32.2	Section 906 Principal Financial Officer Certification.
101*	The following materials from the MAXIMUS, Inc. Quarterly Report on Form 10-Q for the quarter ended June 30, 2011 formatted in eXtensible Business Reporting Language (XBRL): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Cash Flows and (iv) Notes to Unaudited Consolidated Financial Statements

---

\* Submitted electronically herewith